The threat of carbapenem resistance in Eastern Europe in patients with decompensated cirrhosis admitted to intensive care unit

Dig Liver Dis. 2022 Oct;54(10):1385-1391. doi: 10.1016/j.dld.2022.05.011. Epub 2022 Jun 19.

Abstract

Background: Multidrug-resistant organisms are an increasing concern in patients with decompensated cirrhosis.

Aim: We aimed to evaluate the prevalence of infections with carbapenem-resistant Enterobacteriaceae in patients with decompensated cirrhosis.

Methods: Patients with decompensated cirrhosis admitted to ICU were included. The isolated Enterobacteriaceae strains were tested for carbapenemase-producing genes using the Roche LightMix® Modular VIM/IMP/NDM/GES/KPC/OXA48-carbapenemase detection kit.

Results: 48 culture-positive infections were registered in 75 patients with acutely decompensated cirrhosis. Thirty patients contracted a second infection. 46% of bacteria isolated at admission and 60% of bacteria responsible for infections identified during ICU-stay were multiresistant. ESBL+ Enterobacteriaceae were predominant at admission, while carbapenem-resistance was dominant in both Enterobacteriaceae and Non-Fermenting-Gram-Negative Bacteria responsible for infections diagnosed during hospitalisation. OXA 48 or KPC type carbapenemases were present in 30% of the analyzed Enterobacteriaceae and in 40% of the phenotypically carbapenem-resistant Klebsiella pneumoniae strains. The length of ICU stay was a risk-factor for a second infection (p=0.04). Previous carbapenem usage was associated with occurence of infections with carbapenem-resistant Gram-negative bacteria during hospitalization (p=0.03).

Conclusion: The prevalence of infections with carbapenem-resistant Enterobacteriaceae is high in patients with decompensated cirrhosis admitted to ICU. Carbapenemase-producing genes in Enterobacteriaceae in our center are blaOXA-48 and blaKPC.

Keywords: Carbapenems; Cirrhosis; ICU; Multidrug resistant organisms.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Carbapenem-Resistant Enterobacteriaceae* / genetics
  • Carbapenems / pharmacology
  • Carbapenems / therapeutic use
  • Enterobacteriaceae / genetics
  • Hospitalization
  • Humans
  • Intensive Care Units
  • Liver Cirrhosis / epidemiology
  • Microbial Sensitivity Tests

Substances

  • Anti-Bacterial Agents
  • Carbapenems